Health and Fitness Health and Fitness
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012

Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host Conference Call on November 12, 2012


//health-fitness.news-articles.net/content/2012/ .. nd-host-conference-call-on-november-12-2012.html
Published in Health and Fitness on Tuesday, November 6th 2012 at 14:01 GMT by Market Wire   Print publication without navigation


Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host... -- POINT RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ --

POINT RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, November 12, 2012, at 4:30 p.m. Eastern Time to discuss its third quarter 2012 financial results. The conference call will follow the release of the Transcept third quarter 2012 financial results after the close of market that day.

Conference Call Information





Date: Monday, November 12, 2012


Time: 4:30 p.m. ET


Dial-in (U.S.): 877-638-4558


Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at [ www.transcept.com ]. A replay of this webcast will be available on the website shortly after the conclusion of the call through January 30, 2013.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit [ www.transcept.com ]. For information about Intermezzo, please visit [ www.IntermezzoRx.com ].

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]

SOURCE Transcept Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.transcept.com ]

Publication Contributing Sources